Arkolith/Insider Trading/KLRA/Form 4

Koppel Adam

Director, 10% OwnerKailera Therapeutics, Inc. (KLRA) · full profile →Form 4 · filed Apr 20, 2026
Net Buying
Open-Market Buys
$25.0M
Open-Market Sells
$0
Net Open-Market Flow
$25.0M
Transactions
6
3 non-derivative · 3 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Apr 20, 2026Conversion(C)16.9M——16.9M
Apr 20, 2026Conversion(C)4.1M——21.0M
Apr 20, 2026Buy(P)1.6M$16.00$25.0M22.6M

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Apr 20, 2026Conversion(C)16.9M—$00
Apr 20, 2026Conversion(C)4.1M—$00
Apr 16, 2026Grant(A)38K—$038K

Transaction Codes

C
Conversion of a derivative
P
Open-market purchase
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-26-164407) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML